SEB has upgraded its recommendation for the medical technology company Bonesupport to buy from hold and raised its target price to 270 kronor from 260.

The major bank states that a central concern has been alleviated following the release of preliminary sales figures for Q4, as well as a supportive sales outlook for 2026.

"We are turning positive on the stock, given that the share price is down approximately 50 percent from its peak (about a year ago), while our expectations for organic sales growth in the US remain unchanged. Bonesupport is performing strongly: we forecast a compound annual growth rate (CAGR) in sales of 27 percent for the period 2025–2030, a momentum we believe is not yet reflected in the price," the report states.